Skip to main content

Advertisement

Table 2 Characteristics of cross-reacting samples in 5022 women

From: Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study

  Total (any of the three assays) HC2 cobas APTIMA
Cross-reactivity to low-risk genotypes  
 Age  
  <30 years (n = 1683) 75 51 (3.0 %) 34 (2.0 %) 15 (0.9 %)
  ≥30 years (n = 3339) 82 58 (1.7 %) 28 (0.8 %) 20 (0.6 %)
 Concurrent cytology
  Normal (n = 4630) 116 71 (1.5 %) 56 (1.2 %) 29 (0.6 %)
  Abnormal (n = 367) 40 37 (10.1 %) 6 (1.6 %) 6 (1.6 %)
  Inadequate (n = 25) 1 1 (4.0 %) 0 (0.0 %) 0 (0.0 %)
 Histology outcome
  CIN2 (n = 60) 2 2 (3.3 %) 0 (0.0 %) 1 (1.7 %)
  CIN3 or worse (n = 118)a 4 4 (3.4 %) 2 (1.7 %) 1 (0.8 %)
Cross-reactivity to unconfirmed genotypes  
 Age  
  <30 years (n = 1683) 73 15 (0.9 %) 56 (3.3 %) 15 (0.9 %)
  ≥30 years (n = 3339) 150 34 (1.0 %) 106 (3.2 %) 41 (1.2 %)
 Concurrent cytology
  Normal (n = 4630) 214 44 (1.0 %) 157 (3.4 %) 54 (1.2 %)
  Abnormal (n = 367) 7 4 (1.1 %) 3 (0.8 %) 2 (0.5 %)
  Inadequate (n = 25) 2 1 (4.0 %) 2 (8.0 %) 0 (0.0 %)
 Histology outcome
  CIN2 (n = 60) 0 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
  CIN3 or worse (n = 118)a 1 1 (0.8 %) 1 (0.8 %) 1 (0.8 %)
  1. aOf which three cases of cervical cancer